

Laura K Hummers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4724460/publications.pdf>

Version: 2024-02-01

114
papers

6,634
citations

61984

43
h-index

64796

79
g-index

116
all docs

116
docs citations

116
times ranked

6573
citing authors

#	ARTICLE	IF	CITATIONS
1	Slow Colonic Transit in Systemic Sclerosis: An Objective Assessment of Risk Factors and Clinical Phenotype. <i>Arthritis Care and Research</i> , 2023, 75, 289-298.	3.4	5
2	Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 163-174.	1.9	3
3	Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. <i>Arthritis Research and Therapy</i> , 2022, 24, 19.	3.5	8
4	Gastroparesis in systemic sclerosis: a detailed analysis using whole-gut scintigraphy. <i>Rheumatology</i> , 2022, 61, 4503-4508.	1.9	7
5	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. <i>Pilot and Feasibility Studies</i> , 2022, 8, 45.	1.2	3
6	Diastolic Dysfunction in Systemic Sclerosis: Risk Factors and Impact on Mortality. <i>Arthritis and Rheumatology</i> , 2022, 74, 849-859.	5.6	6
7	Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1399-1408.	5.6	9
8	Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States. <i>ACR Open Rheumatology</i> , 2022, 4, 596-602.	2.1	2
9	Troponin elevation independently associates with mortality in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
10	Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis. <i>Lancet Rheumatology</i> , The, 2022, 4, e462-e464.	3.9	6
11	Primary central nervous system lymphoma in scleroderma: A case series. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 214-219.	1.7	0
12	Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures?. <i>Clinical Rheumatology</i> , 2021, 40, 965-971.	2.2	7
13	Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex. <i>Arthritis and Rheumatology</i> , 2021, 73, 315-323.	5.6	19
14	Essential Hypertension Worsens Left Ventricular Contractility in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 1299-1306.	2.0	3
15	Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2137-2147.	1.5	11
16	Systemic sclerosis with associated interstitial lung disease: management considerations and future directions. <i>American Journal of Managed Care</i> , 2021, 27, S138-S146.	1.1	5
17	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101707.	3.3	22
18	Predicting clinical events using Bayesian multivariate linear mixed models with application to scleroderma. <i>BMC Medical Research Methodology</i> , 2021, 21, 249.	3.1	0

#	ARTICLE	IF	CITATIONS
19	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 124-133.	0.8	1
20	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 124-133.	0.8	11
21	Clinical and Molecular Phenotyping in Scleromyxedema Pretreatment and Posttreatment With Intravenous Immunoglobulin. <i>Arthritis Care and Research</i> , 2020, 72, 761-767.	3.4	13
22	Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. <i>Clinical Rheumatology</i> , 2020, 39, 93-102.	2.2	8
23	Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1). <i>Clinical Rheumatology</i> , 2020, 39, 1199-1205.	2.2	6
24	Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1478-1484.	0.9	46
25	The Utility of Plasma Vascular Biomarkers in Systemic Sclerosis: A Prospective Longitudinal Analysis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1341-1349.	5.6	3
26	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1350-1360.	5.6	67
27	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020, 9, e16799.	1.0	7
28	Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-9.	1.7	32
29	Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 405-410.	3.4	15
30	Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2019, 71, 1691-1700.	5.6	15
31	Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. <i>Nature Communications</i> , 2019, 10, 1128.	12.8	28
32	Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. <i>Journal of Rheumatology</i> , 2019, 46, 176-183.	2.0	23
33	Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-212999.	0.9	60
34	Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer. <i>Arthritis Care and Research</i> , 2018, 70, 1517-1524.	3.4	16
35	Determining the Risk Factors and Clinical Features Associated With Severe Gastrointestinal Dysmotility in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2018, 70, 1385-1392.	3.4	28
36	Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). <i>Chest</i> , 2018, 154, 862-871.	0.8	72

#	ARTICLE	IF	CITATIONS
37	Vascular complications in systemic sclerosis: a prospective cohort study. <i>Clinical Rheumatology</i> , 2018, 37, 2429-2437.	2.2	15
38	Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed by the COMPASS-31 Questionnaire. <i>Journal of Rheumatology</i> , 2018, 45, 1145-1152.	2.0	40
39	Brief Report: Anti-RNPA Antibodies As a Marker of Cancer-Associated Scleroderma. <i>Arthritis and Rheumatology</i> , 2017, 69, 1306-1312.	5.6	61
40	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 1915-1916.	5.6	0
41	Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality. <i>Arthritis Care and Research</i> , 2017, 69, 1764-1770.	3.4	35
42	Scleroderma Mimics. , 2017, , 115-123.		1
43	Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 71-74.	0.8	10
44	Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 106-113.	0.8	7
45	Exhaled Nitric Oxide in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis. <i>Pulmonary Circulation</i> , 2016, 6, 545-550.	1.7	8
46	Thrombotic complications after radial arterial line placement in systemic sclerosis: A case series. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 196-199.	3.4	10
47	Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2016, 133, 2413-2422.	1.6	149
48	Unique Abnormalities in Right Ventricular Longitudinal Strain in Systemic Sclerosis Patients. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	2.6	67
49	Scleroderma Mimickers. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 69-84.	1.4	21
50	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 20.	3.5	18
51	Symptomatic and Electrodiagnostic Features of Peripheral Neuropathy in Scleroderma. <i>Arthritis Care and Research</i> , 2016, 68, 1150-1157.	3.4	17
52	Biomarkers in Scleroderma: Progressing from Association to Clinical Utility. <i>Current Rheumatology Reports</i> , 2016, 18, 17.	4.7	12
53	Identification of Rare Variants in <i>ATP8B4</i> as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing. <i>Arthritis and Rheumatology</i> , 2016, 68, 191-200.	5.6	32
54	Spectrum of Muscle Histopathologic Findings in Forty-two Scleroderma Patients With Weakness. <i>Arthritis Care and Research</i> , 2015, 67, 1416-1425.	3.4	56

#	ARTICLE	IF	CITATIONS
55	Biomarkers of pulmonary hypertension in patients with scleroderma: a case-control study. <i>Arthritis Research and Therapy</i> , 2015, 17, 201.	3.5	27
56	Oxalate nephropathy in systemic sclerosis: Case series and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 315-320.	3.4	13
57	Examination of Autoantibody Status and Clinical Features Associated With Cancer Risk and Cancer-Associated Scleroderma. <i>Arthritis and Rheumatology</i> , 2015, 67, 1053-1061.	5.6	93
58	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 680-686.	3.4	60
59	Intravenous Immunoglobulin May Be an Effective Therapy for Refractory, Active Diffuse Cutaneous Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 236-242.	2.0	54
60	Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD). <i>Current Respiratory Medicine Reviews</i> , 2015, 11, 175-183.	0.2	30
61	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014, 69, 436-444.	5.6	100
62	Severity of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension in African Americans. <i>Medicine (United States)</i> , 2014, 93, 177-185.	1.0	27
63	Survival and Predictors of Mortality in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. <i>Arthritis Care and Research</i> , 2014, 66, 489-495.	3.4	132
64	Scleromyxedema. <i>Current Opinion in Rheumatology</i> , 2014, 26, 658-662.	4.3	38
65	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 55-62.	3.4	69
66	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
67	International consensus criteria for the diagnosis of Raynaud's phenomenon. <i>Journal of Autoimmunity</i> , 2014, 48-49, 60-65.	6.5	170
68	Pulmonary Hypertension Associated with Connective Tissue Disease. , 2014, , 139-166.		2
69	Systemic sclerosis-challenges for clinical practice. <i>Nature Reviews Rheumatology</i> , 2013, 9, 90-100.	8.0	28
70	Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1136-1140.	0.9	19
71	Right Ventricular Dysfunction in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. <i>Circulation: Heart Failure</i> , 2013, 6, 953-963.	3.9	225
72	A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1962-1967.	0.9	36

#	ARTICLE	IF	CITATIONS
73	Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. <i>Arthritis Research and Therapy</i> , 2013, 15, R54.	3.5	25
74	Race and Association With Disease Manifestations and Mortality in Scleroderma. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	1.0	100
75	Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1335-1342.	0.9	82
76	<i>IRF5</i> polymorphism predicts prognosis in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1197-1202.	0.9	72
77	Scleroderma Mimics. , 2012, , 103-111.		0
78	Vascular Biomarkers. , 2012, , 247-253.		0
79	Erythroid-Specific Transcriptional Changes in PBMCs from Pulmonary Hypertension Patients. <i>PLoS ONE</i> , 2012, 7, e34951.	2.5	63
80	Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon. <i>Arthritis Care and Research</i> , 2012, 64, 925-929.	3.4	48
81	Systemic Sclerosis 2011. <i>International Journal of Rheumatology</i> , 2011, 2011, 1-2.	1.6	0
82	Aging and scleroderma. <i>Aging Health</i> , 2011, 7, 231-242.	0.3	1
83	Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. <i>Arthritis and Rheumatism</i> , 2011, 63, 2456-2464.	6.7	109
84	Late-age Onset Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2011, 38, 1317-1325.	2.0	53
85	Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1104-1107.	0.9	73
86	Tricuspid Annular Plane Systolic Excursion Is a Robust Outcome Measure in Systemic Sclerosis-associated Pulmonary Arterial Hypertension. <i>Journal of Rheumatology</i> , 2011, 38, 2410-2418.	2.0	102
87	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. <i>PLoS Genetics</i> , 2011, 7, e1002178.	3.5	201
88	Long Term Effects of Cyclophosphamide Treatment on Lung Function and Survival in Scleroderma Patients with Interstitial Lung Disease. <i>Open Rheumatology Journal</i> , 2011, 5, 1-6.	0.2	10
89	Cardiac complications of systemic sclerosis: recent progress in diagnosis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 696-703.	4.3	30
90	The Current State of Biomarkers in Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2010, 12, 34-39.	4.7	21

#	ARTICLE	IF	CITATIONS
91	Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. <i>Arthritis and Rheumatism</i> , 2010, 62, 2787-2795.	6.7	180
92	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. <i>Nature Genetics</i> , 2010, 42, 426-429.	21.4	351
93	Vascular Disease in Systemic Sclerosis. <i>International Journal of Rheumatology</i> , 2010, 2010, 1-2.	1.6	4
94	Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial Hypertension. <i>Journal of Rheumatology</i> , 2010, 37, 98-104.	2.0	88
95	Hemodynamic Predictors of Survival in Scleroderma-related Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 252-260.	5.6	207
96	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1809-1815.	0.9	1,017
97	Abnormalities in the Regulators of Angiogenesis in Patients with Scleroderma. <i>Journal of Rheumatology</i> , 2009, 36, 576-582.	2.0	92
98	Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2009, 60, 569-577.	6.7	223
99	Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor α in a subset of normal and systemic sclerosis patient sera. <i>Arthritis and Rheumatism</i> , 2009, 60, 1145-1151.	6.7	73
100	Regulation of pulmonary inflammation and fibrosis through expression of integrins α 3 and α 5 on pulmonary T lymphocytes. <i>Arthritis and Rheumatism</i> , 2009, 60, 1530-1539.	6.7	71
101	Systemic Sclerosis (Scleroderma) and Raynaud's Phenomenon. , 2009, , 77-95.		0
102	Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. <i>Translational Research</i> , 2008, 151, 197-207.	5.0	81
103	Scleroderma-like Fibrosing Disorders. <i>Rheumatic Disease Clinics of North America</i> , 2008, 34, 199-220.	1.9	103
104	The importance of recognizing scleroderma-type disorders in clinical practice. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 638-640.	3.2	4
105	Biomarkers of vascular disease in scleroderma. <i>Rheumatology</i> , 2008, 47, v21-v22.	1.9	10
106	Scleromyxedema. <i>Medicine (United States)</i> , 2008, 87, 10-20.	1.0	102
107	Antiangiogenic plasma activity in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3448-3458.	6.7	61
108	Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2007, 56, 4195-4202.	6.7	22

#	ARTICLE	IF	CITATIONS
109	Microvascular damage in systemic sclerosis: Detection and monitoring with biomarkers. <i>Current Rheumatology Reports</i> , 2006, 8, 131-137.	4.7	12
110	Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. <i>Arthritis and Rheumatism</i> , 2006, 54, 3043-3050.	6.7	308
111	Paclitaxel Modulates TGF β 2 Signaling in Scleroderma Skin Grafts in Immunodeficient Mice. <i>PLoS Medicine</i> , 2005, 2, e354.	8.4	50
112	Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2003, 29, 293-313.	1.9	88
113	Increased Microchimeric CD4+ T Lymphocytes in Peripheral Blood from Women with Systemic Sclerosis. <i>Clinical Immunology</i> , 2002, 103, 303-308.	3.2	65
114	Troponin elevation independently associates with mortality in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1